Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of envafolimab plus lenvatinib combined with TACE in unresectable hepatocellular carcinoma: An open-label, single-arm, phase 2 study—The CISLD-12 study.
Authors
Tingbo Liang
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;
Tingbo Liang , Yiwen Chen , Xin Huang , Wendi Hu , Xiang Li , Junhui Sun , Yan Shen , Min Zhang , Jian Wu , Shunliang Gao , Jun Yu , Risheng Que , Yun Zhang , Fuchun Yang , Weiliang Xia , Aibin Zhang , Xiaofeng Tang , Xueli Bai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05213221
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 558)
DOI
10.1200/JCO.2023.41.4_suppl.558
Abstract #
558
Poster Bd #
D10
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Lenvatinib (LEN) combined with tislelizumab (TIS) plus transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II clinical trial.
First Author: Xiang Nong
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Fruquintinib combined with sintilimab plus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma: A single-arm phase II study.
First Author: Guoliang Shao
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study.
First Author: Yongkang Xu
Poster
2024 ASCO Annual Meeting
PD-1 inhibitor (sintilimab) and lenvatinib plus TACE-HAIC as conversion therapy for initially unresectable HCC: A single-arm, phase 2 clinical trial (PLATIC).
First Author: Yunfei Yuan